Mohini Ranganathan
Overview
Explore the profile of Mohini Ranganathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
DSouza D, Syed S, Flynn L, Safi-Aghdam H, Cozzi N, Ranganathan M
Neuropsychopharmacology
. 2022 Jun;
47(10):1854-1862.
PMID: 35660802
There is considerable interest in the therapeutic potential of psychedelic drugs. Dimethyltryptamine (DMT) is a potent, rapid-onset, and short-acting psychedelic drug that has not yet been independently tested for the...
12.
Abdallah C, Roache J, Gueorguieva R, Averill L, Young-McCaughan S, Shiroma P, et al.
Neuropsychopharmacology
. 2022 May;
47(8):1583-1584.
PMID: 35545665
No abstract available.
13.
Bassir Nia A, Orejarena M, Flynn L, Luddy C, DSouza D, Skosnik P, et al.
Psychopharmacology (Berl)
. 2022 Apr;
239(5):1621-1628.
PMID: 35438304
Background: Cannabis is the most common illicit drug used in the USA and its use has been rising over the past decade, while the historical gap in rates of use...
14.
Selloni A, Bhatia G, Ranganathan M, Aquino J
J Dual Diagn
. 2022 Apr;
18(2):81-91.
PMID: 35430960
Cannabis use (CU) is common among persons with bipolar disorder (BD). Evidence suggests that CU is associated with poorer outcomes among persons with BD; however, these findings remain inconsistent. The...
15.
Ganesh S, Cortes-Briones J, Schnakenberg Martin A, Skosnik P, DSouza D, Ranganathan M
Cannabis Cannabinoid Res
. 2022 Mar;
8(5):846-856.
PMID: 35319274
THC and CBD are the principal phyto-cannabinoids in the cannabis plant. The differential and possibly antagonistic effects of these compounds on specific brain and behavioral responses, and the mechanisms underlying...
16.
DSouza D, DiForti M, Ganesh S, George T, Hall W, Hjorthoj C, et al.
World J Biol Psychiatry
. 2022 Mar;
23(10):719-742.
PMID: 35315315
Objectives: The liberalisation of cannabis laws, the increasing availability and potency of cannabis has renewed concern about the risk of psychosis with cannabis. Methods: The objective of the WFSBP task...
17.
Averill L, Averill C, Gueorguieva R, Fouda S, Sherif M, Ahn K, et al.
J Affect Disord
. 2022 Feb;
303:91-97.
PMID: 35101523
Suicide is a public health crisis with limited treatment options. Ketamine has demonstrated rapid and robust improvements in suicidal ideation (SI). The parent study for the secondary pilot analyses presented...
18.
Abdallah C, Roache J, Gueorguieva R, Averill L, Young-McCaughan S, Shiroma P, et al.
Neuropsychopharmacology
. 2022 Jan;
47(8):1574-1581.
PMID: 35046508
This study tested the efficacy of repeated intravenous ketamine doses to reduce symptoms of posttraumatic stress disorder (PTSD). Veterans and service members with PTSD (n = 158) who failed previous...
19.
Abi-Dargham A, Javitch J, Slifstein M, Anticevic A, Calkins M, Cho Y, et al.
Schizophr Bull
. 2021 Aug;
48(1):199-210.
PMID: 34423843
Decades of research have highlighted the importance of optimal stimulation of cortical dopaminergic receptors, particularly the D1R receptor (D1R), for prefrontal-mediated cognition. This mechanism is particularly relevant to the cognitive...
20.
Radhakrishnan R, Skosnik P, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, et al.
Mol Psychiatry
. 2021 Jun;
26(12):7690-7698.
PMID: 34135473
Decreased synaptic spine density has been the most consistently reported postmortem finding in schizophrenia (SCZ). A recently developed in vivo measure of synaptic vesicle density estimated using the novel positron...